Who's going to carry the logs
Swing Trader
ClearPoint Neuro has many irons in the fire beyond uniQure, one of its 60+ partners, which still has a decent probability of BLA acceptance in November. Neurona's MTLE drug and Parkinson's partners are enrolling, and gene and cell therapy delivered into the brain is not going to slow down. x.comÂ
ClearPoint Neuro's prospects hinge on uniQure: approval of uniQure's therapy would be a paradigm shift for ClearPoint's drug delivery business. As a platform with trials in Parkinson's, epilepsy and other areas, ClearPoint carries less binary risk than uniQure itself, though a rejection would be terrible for it. The guidance miss is not great, the core business has grown slower than hoped, and bears have been right on dilution, management and valuation. x.com x.comÂ
uniQure's risk/reward is attractive because $10-12 of cash per share plus the upside implies the market assigns a low chance of approval. Management communication was the core issue rather than a change to the endgame; the unmet need is huge and the company is likely closer to the finish line than the start. The prespecified cUHDRS base and bull case was missed, possibly because of attrition, but being negative here is fundamentally betting the drug doesn't work. x.comÂ
uniQure's AMT-130 likely still gets approved and can be a reasonable commercial success. The open questions are insurance coverage and pricing, and whether Huntington's disease patients will pay given there is no other treatment. x.comÂ
uniQure's risk/reward is too high, as the stock has become a binary bet on regulatory and clinical outcomes. The earlier drop came because the FDA asked for a larger trial, a huge setback, yet the stock has since doubled as investors bet on success given very strong efficacy data. Future moves will hinge on regulatory and clinical catalysts, and the chart shows huge swings all the time. x.comÂ
uniQure offers a much better risk-reward after today's news than before the November setback, as @LogicalThesis points out. As clarity on AMT-130's approval builds, it could return to or surpass its October level of about $70, though the market still has trust issues after what happened. If things turn negative again, the case is over. x.comÂ
Commercialization by at least a handful of ClearPoint Neuro's partners should make its shares 10x higher over ten years. x.comÂ
uniQure and ClearPoint Neuro look very bullish on the Wall Street Journal report that President Trump is expected to remove FDA Commissioner Marty Makary. x.comÂ
ClearPoint Neuro would become a cash-flow machine if uniQure's AMT-130 reaches commercial launch, and after today's positive reversal it is a much better risk-reward than before the event, as @LogicalThesis points out. Commercial partners pay more for equipment and consumables than trial partners, and royalties flow straight to the bottom line. With more clarity on approval it could regain or pass its October 2025 peak near $30. Without an anchor commercial partner it is far less attractive. … Show more
Taysha Gene Therapies is a high-conviction binary bet: cash cushions the downside, and FDA approval of TSHA-102 for Rett syndrome could be a 5-10x event. No disease-modifying Rett therapy exists today, and TSHA-102 has a clean safety record in 12 patients, while rival Neurogene's NGN-401 lost its high-dose arm after a patient death. Comparables suggest $2-4 million a dose against about $10,000 in cost. Cash of $319.8 million lasts into 2028, but another raise is likely; failure means near zero. … Show more
